Dendritic cell vaccine - Medigene

Drug Profile

Dendritic cell vaccine - Medigene

Alternative Names: DC vaccine - Medigene Immunotherapies; DC Vaccine for AML - Medigene Immunotherapies; DC Vaccine for prostate cancer - Medigene Immunotherapies; IL-12p70 DC vaccine; Leukemia-associated RNA transfected autologous dendritic cell vaccine - Medigene Immunotherapies

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Trianta Immunotherapies
  • Developer Ludwig-Maximilians-University; Medigene Immunotherapies; University of Oslo
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Prostate cancer

Most Recent Events

  • 03 Dec 2016 Immunogenicity and adverse event data from a phase I/II trial in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 16 Apr 2016 Efficacy data from a phase I/II trial in Prostate cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 01 Apr 2016 Phase-II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Norway (Intradermal) (NCT02405338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top